RT Journal Article
SR Electronic
T1 Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1699
OP 1703
DO 10.21873/anticanres.13275
VO 39
IS 4
A1 CROSSLEY, RACHEL A.
A1 MATZ, ALYSSA
A1 DEW, TERRY
A1 KALINAUSKAS, ASHLEY
A1 FAUCETTE, NICOLE
A1 POFF, BRAD
A1 SILBART, LAWRENCE K.
A1 SUCKOW, MARK A.
YR 2019
UL http://ar.iiarjournals.org/content/39/4/1699.abstract
AB Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.